CD281抗体;CD281 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD281 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using CD281 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human lung tissues using CD281 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human kidney cancer tissues using CD281 mouse mAb with DAB staining.    

  
  

CD281. also known as Toll-like receptor 1 (TLR1), is a member of the TLR family that plays a critical role in the innate immune system by recognizing pathogen-associated molecular patterns (PAMPs). TLR1 is a transmembrane protein predominantly expressed on immune cells, including monocytes, macrophages, and dendritic cells. It functions by forming heterodimers with TLR2 to detect bacterial lipoproteins and other microbial components, triggering downstream signaling pathways (e.g., NF-κB activation) that promote inflammatory responses and adaptive immunity.

CD281 antibodies are essential tools for studying TLR1’s structural features, ligand interactions, and signaling mechanisms. They are widely used in applications such as Western blotting, flow cytometry, and immunofluorescence to investigate TLR1 expression patterns in health and disease. Research has linked TLR1 polymorphisms to altered susceptibility to infections (e.g., tuberculosis) and inflammatory disorders, highlighting its therapeutic relevance.

Developing CD281 antibodies requires careful validation to ensure specificity, given the structural similarities among TLR family members. These antibodies also hold potential for therapeutic exploration, such as modulating TLR1 activity in chronic inflammation or vaccine adjuvants. However, challenges remain in balancing immune activation and avoiding off-target effects. Overall, CD281 antibodies are pivotal in advancing our understanding of innate immunity and TLR-targeted therapies.